Loading company…
TRIMTECH develops therapies that target protein aggregation in central nervous system and inflammatory disorders.
TRIMTECH develops TRIMTACs™ and TRIMGLUEs™ to target and eliminate disease-causing protein aggregates, with a focus on central nervous system and inflammatory disorders. It raised EUR 12 million in seed funding in June 2026, co-led by Johnson & Johnson Innovation and BGF Investment Management, with Cambridge Innovation Capital, Pfizer Venture Investments, Eli Lilly & Company, MP Healthcare Venture Management, M Ventures and Cambridge Enterprise Ventures participating.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in